AURORA, ON--(Marketwired - December 17, 2013) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Mario Gobbo has resigned from Helix's board of directors.
Commenting on the resignation, Robert A. Verhagen, Helix's Chief Executive Officer, said, "Mr. Gobbo became a director in March 2012 and subsequently assumed the role of Chair of the board in January 2013. He also served on each of the audit, compensation and governance committees of the board during his tenure, including as chair of the audit committee and, most recently, the governance committee. Mr. Gobbo served on the board during a period of transition as Helix made a number of key business and strategic decisions to refocus itself and its operations. We thank Mr. Gobbo for his service and wish him well in the future."
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".